SCHEMBL855127

SCHEMBL855127

CCC1(C(C)=O)Cc2ccccc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.42
NOTUM Q6P988 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HDAC9 Q9UKV0 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
ADRA1B P35368 1/20 0.37
CETP P11597 1/20 0.36
BRD4 O60885 1/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
MPI P34949 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MMP8 P22894 1/20 0.35
CXCR5 P32302 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9527366 0.89 ATM (0.42) MMENOTUMSMN1; SMN2
SCHEMBL857043 0.84 MME (0.46) MMENPSR1HDAC9ADRA2AADRA2B
SCHEMBL31034835 0.84 MME (0.46) MMENPSR1HDAC9ADRA2AADRA2B
Hydrochloric Acid SCHEMBL856898 0.82 MME (0.45) MMENPSR1HDAC9BRD4MMP8
SCHEMBL31034935 0.82 MME (0.41) MMENOTUMNPSR1ALDH1A1HDAC9
SCHEMBL31034910 0.82 MME (0.41) MMENOTUMNPSR1ALDH1A1HDAC9
SCHEMBL856896 0.82 MME (0.41) MMENOTUMNPSR1ALDH1A1HDAC9
SCHEMBL27796327 0.82 MME (0.41) MMENOTUMNPSR1HDAC9ADRA2A
SCHEMBL21916128 0.81 MME (0.47) MMENOTUMALDH1A1HDAC9MMP8
SCHEMBL9527354 0.80 NOTUM (0.37) NOTUMNPSR1ALDH1A1ADRA2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117186010-A Synthesis method of atimetazole hydrochloride 厦门欧瑞捷生物科技有限公司 2023-12-08 CN disclosed
CN-112225700-B Preparation method of atemezole 湖南新合新生物医药有限公司 2023-11-17 CN disclosed
CN-112225700-A Preparation method of altimezole 湖南新合新生物医药有限公司 2021-01-15 CN disclosed
EP-2456749-B1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM PHARMA CHEMICALS REGENSBURG GMBH (DE) 2016-03-30 EP disclosed
US-8563766-B2 Indane derivatives for use as intermediates DSM PHARMA CHEMICALS (DE) 2013-10-22 US disclosed
US-8431717-B2 Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof JSC GRINDEKS (LV) 2013-04-30 US disclosed
US-20120190881-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM PHARMA CHEMICALS (DE) 2012-07-26 US disclosed
CN-102548951-A Indane derivatives as intermediates DSM PHARMA CHEMICALS REGENSBURG GMBH 2012-07-04 CN disclosed
EP-2456749-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM Pharma Chemicals Regensburg GmbH (DE) 2012-05-30 EP disclosed
EP-2225209-B1 PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF GRINDEKS JSC (LV) 2012-03-28 EP disclosed
US-20110028733-A1 PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF JSC GRINDEKS (LV) 2011-02-03 US disclosed
WO-2011009928-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM PHARMA CHEMICALS REGENSBURG GMBH (DE) 2011-01-27 WO disclosed
CN-101889003-A Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof GRINDEKS JSC 2010-11-17 CN disclosed
EP-2225209-A1 PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF Grindeks, a joint stock company (LV) 2010-09-08 EP disclosed
WO-2009071584-A1 PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF GRINDEKS, A JOINT STOCK COMPANY (LV) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028733-A1 PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF CYP3A5, CYP3A4, IPO5 MME 1522/4885NOTUM 2023/4885NPSR1 3167/4885
US-20120190881-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES CYP1A1, CYP1A2, CYP1B1 MME 4580/4885NOTUM 2060/4885NPSR1 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.